IP Library Granted Patent US 9,974,832
Granted Patent B2
US 9,974,832 · App. 12/068,742 · Granted May 22, 2018

Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury

Inventors: Ofer Zohar (Gaithersburg, MD); Daniel L. Alkon (Bethesda, MD)
Assignee: Cognitive Research Enterprises, Inc.
A61K38/1825A61K31/00A61K31/05A61K31/335A61K31/35A61K31/365A61K31/395A61K31/4015A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,974,832
App. No.
12/068,742
Granted
May 22, 2018
Kind
B2
Abstract

The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat head trauma. Specifically, the present invention provides methods of treating head trauma comprising the steps of identifying a subject having suffered a head trauma and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of head trauma.

Claims (14)

1. A method of treating post-head trauma memory deficits resulting from brain injury comprising the steps of identifying a human subject having suffered a brain injury resulting from head trauma and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator, and a pharmaceutically acceptable carrier effective to treat at least one symptom of head trauma, wherein the PKC activator is chosen from

wherein R is t-Bu, Ph, or (CH 2 ) 3 p-Br-Ph, and

wherein the administration is initiated within 3 days of the head trauma and is continued for a duration in a range from about 1 week to about 12 weeks.

2. The method of claim 1 , wherein the PKC activator has a molecular weight from about 600 to 755 and an affinity for PKC from about 0.25 nM to 10 μM.

3. The method of claim 1 , wherein said administration is initiated within 1 day of said head trauma.

4. The method of claim 1 , wherein said administration is initiated within 2 days of said head trauma.

5. The method of claim 1 , wherein said administration is initiated within 3 days of said head trauma.

6. The method of claim 1 , wherein said administration is initiated between 1 and 2 days of said head trauma.

7. The method of claim 1 , wherein said administration is initiated between 1 and 3 days of said head trauma.

8. The method of claim 1 , wherein the treatment is continued for a duration of 1 week.

9. The method of claim 1 , wherein the treatment is continued for a duration of 2 weeks.

10. The method of claim 1 , wherein the treatment is continued for a duration of 3 weeks.

11. The method of claim 1 , wherein the treatment is continued for a duration of 4 weeks.

12. The method of claim 1 , wherein the treatment is continued for a duration of 6 weeks.

Assignments (3)
CHANGE OF NAME Recorded Oct 12, 2016
From: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE, INC.
To: COGNITIVE RESEARCH ENTERPRISES, INC.
Reel/Frame 039994/0260 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2010
From: ALKON, DANIEL L.
To: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE
Reel/Frame 024293/0236 →
EMPLOYMENT AGREEMENT ASSIGNING PATENT RIGHTS Recorded Apr 12, 2010
From: ZOHAR, OFER
To: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE
Reel/Frame 024215/0404 →
Continuity (3)
Provisional Application 60900338 · Feb 9, 2007
Provisional Application 60924663 · May 24, 2007
Related Publication 20080207742A1 · Aug 28, 2008